晚期结肠癌与直肠癌化疗近期疗效差异分析(2)
 |
| 第1页 |
参见附件。
[参考文献]
[1] Garcia-Alfonso P. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status[J].Angiogenesis，2014.
[2] Slattery M L.Genetic variation in RPS6KA1， RPS6KA2， RPS6KB1， RPS6KB2， and PDK1 and risk of colon or rectal cancer[J].Mutat Res， 2011，706(1/2)：13-20.
[3] Bohn B A. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer[J].Hum Pathol， 2013， 44(8)： 1524-1533.
[4] Hugen N. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype[J].Ann Oncol， 2014，25(3)：651-657.
[5] Fabian C J. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy[J].Breast Cancer Res Treat， 2007，106(1)：75-84.
[6] Cameron J. and S. Waterworth， Patients' experiences of ongoing palliative chemotherapy for metastatic colorectal cancer： a qualitative study[J]. Int J Palliat Nurs， 2014，20(5)：218-224.
[7] Li M. Colorectal cancer or colon and rectal cancer Clinicopathological comparison between colonic and rectal carcinomas[J].Oncology，2007，73(1/2)：52-57.
[8] Kornmann M. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer[J].Clin Colorectal Cancer，2013，12(1)： 54-61.
[9] 羅秦英.奥沙利铂或伊立替康联合卡培他滨治疗转移性结直肠癌的临床研究[J].中华临床医师杂志， 2013(17)： 7767-7771.
[10] 刘倩雯，李海聪.卡培他滨联合奥沙利铂一线治疗晚期结肠癌的疗效观察[J].中国实用医药，2014(9)：174-175.
(收稿日期：2014-05-25)
您现在查看是摘要介绍页，详见PDF附件。